|
|
|
|
| LEADER |
04651nmm a2200385 u 4500 |
| 001 |
EB000709271 |
| 003 |
EBX01000000000000000562353 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9783709189948
|
| 100 |
1 |
|
|a Przuntek, Horst
|e [editor]
|
| 245 |
0 |
0 |
|a Early Diagnosis and Preventive Therapy in Parkinson’s Disease
|h Elektronische Ressource
|c edited by Horst Przuntek, Peter Riederer
|
| 250 |
|
|
|a 1st ed. 1989
|
| 260 |
|
|
|a Vienna
|b Springer Vienna
|c 1989, 1989
|
| 300 |
|
|
|a XIV, 447 p
|b online resource
|
| 505 |
0 |
|
|a Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease -- Evoked potentials in Parkinson’s disease -- Brain mapping of EEG and evoked potentials during physiological aging and in Parkinson’s disease, dementia and depression -- Positron emission tomography in Parkinson’s disease glucose metabolism -- Parkinson’s disease studied using PET -- Pathobiochemistry of the extrapyramidal system: a “short note” review -- Dopaminergic neurotransmission and status of brain iron -- Dopaminergic modulation of neuropeptide gene expression in the rat striatum -- The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease -- Cytoskeletal pathology of the Lewy bodies -- Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitorRo41-0960 -- Catecholamines in urine, blood and cerebrospinal fluid --
|
| 505 |
0 |
|
|a The premorbid personality of patients with Parkinson’s disease -- Parkinson’s disease: development of dementia in aging -- Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease — an update -- Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent -- Autonomic nervous system screening in patients with early Parkinson’s disease -- Clinical and biochemical characteristics of early depression in Parkinson’s disease -- Psychomotor investigations in depressed patients by comparison with Parkinson patients -- Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease -- Motor performance test -- Measuring body movements in neurological disease, with special reference to Parkinson’s disease -- Long-term measurement of tremor: early diagnostic possibilities --
|
| 505 |
0 |
|
|a 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients -- Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro19-6327 -- Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease -- Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease -- The MPTP model: an update -- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease? -- Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity -- Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists? -- Pharmacological and clinical-pharmacological aspects of D1- and D2-receptors -- Chemical modulation of membrane-bound receptors -- Transplantation of dopamine-synthesizing cells — new therapy for Parkinson’s disease? --
|
| 505 |
0 |
|
|a L-dopa in Parkinson’s disease -- Pharmacokinetic investigations of various levodopa formulations -- Iron therapy in Parkinson’s disease. Stimulation of endogenous presynaptic L-DOPA biosynthesis by the iron compound oxyferriscorbone -- Provisional experiences with the combination of L-dopa and L-deprenyl -- Clinical pharmacology of amantadine and derivatives -- Dopamine agonist treatment in early Parkinson’s disease -- Subcutaneous apomorphine in Parkinson’s disease -- Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease -- Discussion
|
| 653 |
|
|
|a Neuroscience
|
| 653 |
|
|
|a Neurosciences
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Neurology
|
| 653 |
|
|
|a Neurology
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a Biochemistry
|
| 653 |
|
|
|a Pharmacology
|
| 700 |
1 |
|
|a Riederer, Peter
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Key Topics in Brain Research
|
| 028 |
5 |
0 |
|a 10.1007/978-3-7091-8994-8
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7091-8994-8?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.8
|